{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T16:42:45Z","timestamp":1750264965605,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive malignancies. Our previous work revealed Chitinase 3-like 1 (CHI3L1) involvement in PDAC resistance to gemcitabine, identifying it as a promising therapeutic target. Here, we aimed to identify putative CHI3L1 inhibitors and to investigate their chemosensitizing potential in PDAC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Docking analysis for CHI3L1 identified promising CHI3L1 inhibitors, including darifenacin (muscarinic receptor antagonist). PDAC cell lines (BxPC-3, PANC-1) and primary PDAC cells were used to evaluate darifenacin\u2019s effects on cell growth (Sulforhodamine B, SRB), alone or in combination with gemcitabine or gemcitabine plus paclitaxel. Cytotoxicity against normal immortalized pancreatic ductal cells (HPNE) was assessed. Recombinant protein was used to confirm the impact of darifenacin on CHI3L1-induced PDAC cellular resistance to therapy (SRB assay). Darifenacin\u2019s effect on Akt activation was analysed by ELISA. The association between cholinergic receptor muscarinic 3 (CHRM3) expression and therapeutic response was evaluated by immunohistochemistry of paraffin-embedded tissues from surgical resections of a 68 patients\u2019 cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:italic>In silico<\/jats:italic> screening revealed the ability of darifenacin to target CHI3L1 with high efficiency. Darifenacin inhibited PDAC cell growth, with a GI<jats:sub>50<\/jats:sub> of 26 and 13.6 \u00b5M in BxPC-3 and PANC-1 cells, respectively. These results were confirmed in primary PDAC-3 cells, while darifenacin showed no cytotoxicity against HPNE cells. Importantly, darifenacin sensitized PDAC cells to standard chemotherapies, reverted CHI3L1-induced PDAC cellular resistance to therapy, and decreased Akt phosphorylation. Additionally, high CHMR3 expression was associated with low therapeutic response to gemcitabine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This work highlights the potential of darifenacin as a chemosensitizer for PDAC treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-024-04712-1","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T08:02:53Z","timestamp":1725350573000},"page":"585-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma"],"prefix":"10.1007","volume":"94","author":[{"given":"Sofia M.","family":"Sousa","sequence":"first","affiliation":[]},{"given":"Helena","family":"Branco","sequence":"additional","affiliation":[]},{"given":"Amir","family":"Avan","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Palmeira","sequence":"additional","affiliation":[]},{"given":"Luca","family":"Morelli","sequence":"additional","affiliation":[]},{"given":"L\u00facio L.","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7801-4643","authenticated-orcid":false,"given":"M. Helena","family":"Vasconcelos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-1917","authenticated-orcid":false,"given":"Cristina P. R.","family":"Xavier","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"4712_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA: a cancer journal for clinicians 73. 117\u201348. https:\/\/doi.org\/10.3322\/caac.21763","DOI":"10.3322\/caac.21763"},{"key":"4712_CR2","doi-asserted-by":"publisher","first-page":"5389820","DOI":"10.1155\/2018\/5389820","volume":"2018","author":"L Kunovsky","year":"2018","unstructured":"Kunovsky L, Tesarikova P, Kala Z, Kroupa R, Kysela P, Dolina J, Trna J (2018) The use of biomarkers in Early Diagnostics of Pancreatic Cancer. Can J Gastroenterol Hepatol 2018:5389820\u20135389820. https:\/\/doi.org\/10.1155\/2018\/5389820","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"8","key":"4712_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A (2023) Pancreatic cancer: advances and challenges. Cell 186(8):1729\u20131754. https:\/\/doi.org\/10.1016\/j.cell.2023.02.014","journal-title":"Cell"},{"issue":"2","key":"4712_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV (2020) Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 12(2):173\u2013181. https:\/\/doi.org\/10.4251\/wjgo.v12.i2.173","journal-title":"World J Gastrointest Oncol"},{"key":"4712_CR5","doi-asserted-by":"publisher","first-page":"100864","DOI":"10.1016\/j.drup.2022.100864","volume":"64","author":"M Capula","year":"2022","unstructured":"Capula M, Peran M, Xu G, Donati V, Yee D, Gregori A, Assaraf YG, Giovannetti E, Deng D (2022) Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug Resist Updat 64:100864. https:\/\/doi.org\/10.1016\/j.drup.2022.100864","journal-title":"Drug Resist Updat"},{"key":"4712_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.03.002","author":"R Rebelo","year":"2023","unstructured":"Rebelo R, Xavier CPR, Giovannetti E, Vasconcelos MH (2023) Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol Med. https:\/\/doi.org\/10.1016\/j.molmed.2023.03.002","journal-title":"Trends Mol Med"},{"issue":"7","key":"4712_CR7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/ijms18071338","volume":"18","author":"A Adamska","year":"2017","unstructured":"Adamska A, Domenichini A, Falasca M (2017) Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci 18(7):1338. https:\/\/doi.org\/10.3390\/ijms18071338","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4712_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12885-018-5240-6","volume":"19","author":"UM Vogl","year":"2019","unstructured":"Vogl UM, Andalibi H, Klaus A, Vormittag L, Schima W, Heinrich B, Kafka A, Winkler T, \u00d6hler L (2019) Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? BMC Cancer 19(1):28\u201328. https:\/\/doi.org\/10.1186\/s12885-018-5240-6","journal-title":"BMC Cancer"},{"key":"4712_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.canlet.2020.11.013","volume":"501","author":"CPR Xavier","year":"2021","unstructured":"Xavier CPR, Castro I, Caires HR, Ferreira D, Cavadas B, Pereira L, Santos LL, Oliveira MJ, Vasconcelos MH (2021) Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine. Cancer Lett 501:210\u2013223. https:\/\/doi.org\/10.1016\/j.canlet.2020.11.013","journal-title":"Cancer Lett"},{"issue":"1","key":"4712_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/1055-9965.EPI-19-0672","volume":"29","author":"IM Chen","year":"2020","unstructured":"Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Bojesen SE, Pfeiffer P, Bjerregaard JK, Nielsen SE, Andersen F, Hollander NH, Yilmaz MK, Rasmussen LS, Johansen JS (2020) Prognostic value of combined detection of serum IL6, YKL-40, and C-reactive protein in patients with unresectable pancreatic Cancer. Cancer Epidemiol Biomarkers Prev 29(1):176\u2013184. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0672","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"4712_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/MPA.0000000000000751","volume":"46","author":"HT Chen","year":"2017","unstructured":"Chen HT, Zheng JM, Zhang YZ, Yang M, Wang YL, Man XH, Chen Y, Cai QC, Li ZS (2017) Overexpression of YKL-40 predicts poor prognosis in patients undergoing curative resection of pancreatic Cancer. Pancreas 46(3):323\u2013334. https:\/\/doi.org\/10.1097\/MPA.0000000000000751","journal-title":"Pancreas"},{"issue":"1","key":"4712_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-023-01131-9","volume":"56","author":"JE Yu","year":"2024","unstructured":"Yu JE, Yeo IJ, Han SB, Yun J, Kim B, Yong YJ, Lim YS, Kim TH, Son DJ, Hong JT (2024) Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer. Exp Mol Med 56(1):1\u201318. https:\/\/doi.org\/10.1038\/s12276-023-01131-9","journal-title":"Exp Mol Med"},{"key":"4712_CR13","doi-asserted-by":"publisher","unstructured":"Chang MC, Chen CT, Chiang PF, Chiang YC (2024) The role of Chitinase-3-like Protein-1 (YKL40) in the therapy of Cancer and other chronic-inflammation-related diseases. Pharmaceuticals (Basel) 17(3). https:\/\/doi.org\/10.3390\/ph17030307","DOI":"10.3390\/ph17030307"},{"issue":"1","key":"4712_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","volume":"5","author":"T Zhao","year":"2020","unstructured":"Zhao T, Su Z, Li Y, Zhang X, You Q (2020) Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct Target Ther 5(1):201. https:\/\/doi.org\/10.1038\/s41392-020-00303-7","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"4712_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.imbio.2015.11.014","volume":"221","author":"M Di Rosa","year":"2016","unstructured":"Di Rosa M, Distefano G, Zorena K, Malaguarnera L (2016) Chitinases and immunity: ancestral molecules with new functions. Immunobiology 221(3):399\u2013411. https:\/\/doi.org\/10.1016\/j.imbio.2015.11.014","journal-title":"Immunobiology"},{"issue":"34","key":"4712_CR16","doi-asserted-by":"publisher","first-page":"25803","DOI":"10.1016\/S0021-9258(19)74461-5","volume":"268","author":"BE Hakala","year":"1993","unstructured":"Hakala BE, White C, Recklies AD (1993) Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268(34):25803\u201325810","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"4712_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1046\/j.1432-1327.1998.2510504.x","volume":"251","author":"GH Renkema","year":"1998","unstructured":"Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JM (1998) Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 251(1\u20132):504\u2013509. https:\/\/doi.org\/10.1046\/j.1432-1327.1998.2510504.x","journal-title":"Eur J Biochem"},{"key":"4712_CR18","doi-asserted-by":"crossref","unstructured":"Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW (2003) Crystal structure of human cartilage gp39 (HC-gp39) in complex with chitotetraose. https:\/\/www.rcsb.org\/structure\/1NWU","DOI":"10.2210\/pdb1nwu\/pdb"},{"issue":"32","key":"4712_CR19","doi-asserted-by":"publisher","first-page":"30206","DOI":"10.1074\/jbc.M303371200","volume":"278","author":"DR Houston","year":"2003","unstructured":"Houston DR, Recklies AD, Krupa JC, van Aalten DM (2003) Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J Biol Chem 278(32):30206\u201330212. https:\/\/doi.org\/10.1074\/jbc.M303371200","journal-title":"J Biol Chem"},{"issue":"39","key":"4712_CR20","doi-asserted-by":"publisher","first-page":"37753","DOI":"10.1074\/jbc.M303137200","volume":"278","author":"F Fusetti","year":"2003","unstructured":"Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW (2003) Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem 278(39):37753\u201337760. https:\/\/doi.org\/10.1074\/jbc.M303137200","journal-title":"J Biol Chem"},{"issue":"3","key":"4712_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/ph14030280","volume":"14","author":"R Rebelo","year":"2021","unstructured":"Rebelo R, Pol\u00f3nia B, Santos LL, Vasconcelos MH, Xavier CPR (2021) Drug Repurposing opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals (Basel) 14(3):280","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"4712_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ (2016) Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 11(5):905\u2013919. https:\/\/doi.org\/10.1038\/nprot.2016.051","journal-title":"Nat Protoc"},{"issue":"D1","key":"4712_CR23","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46(D1):D1074\u2013d1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"4712_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"issue":"5","key":"4712_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","volume":"24","author":"D Seeliger","year":"2010","unstructured":"Seeliger D, de Groot BL (2010) Ligand docking and binding site analysis with PyMOL and Autodock\/Vina. J Comput Aided Mol Des 24(5):417\u2013422. https:\/\/doi.org\/10.1007\/s10822-010-9352-6","journal-title":"J Comput Aided Mol Des"},{"issue":"1","key":"4712_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10822-010-9395-8","volume":"25","author":"MA Lill","year":"2011","unstructured":"Lill MA, Danielson ML (2011) Computer-aided drug design platform using PyMOL. J Comput Aided Mol Des 25(1):13\u201319. https:\/\/doi.org\/10.1007\/s10822-010-9395-8","journal-title":"J Comput Aided Mol Des"},{"key":"4712_CR27","doi-asserted-by":"publisher","unstructured":"Branco H, Oliveira J, Antunes C, Santos LL, Vasconcelos MH, Xavier CPR (2022) Pirfenidone sensitizes NCI-H460 Non-small Cell Lung Cancer cells to Paclitaxel and to a combination of Paclitaxel with Carboplatin. Int J Mol Sci 23(7). https:\/\/doi.org\/10.3390\/ijms23073631","DOI":"10.3390\/ijms23073631"},{"key":"4712_CR28","doi-asserted-by":"publisher","first-page":"44686","DOI":"10.1038\/srep44686","volume":"7","author":"M Rovithi","year":"2017","unstructured":"Rovithi M, Avan A, Funel N, Leon LG, Gomez VE, Wurdinger T, Griffioen AW, Verheul HM, Giovannetti E (2017) Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Sci Rep 7:44686. https:\/\/doi.org\/10.1038\/srep44686","journal-title":"Sci Rep"},{"key":"4712_CR29","doi-asserted-by":"publisher","unstructured":"Silva BR, Rebelo R, Rodrigues JM, Xavier CPR, Vasconcelos MH, Queiroz MRP (2021) Synthesis of Novel Methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates and antitumor activity evaluation: studies in Vitro and in Ovo grafts of Chick Chorioallantoic membrane (CAM) with a Triple negative breast Cancer Cell line. Molecules 26(6). https:\/\/doi.org\/10.3390\/molecules26061594","DOI":"10.3390\/molecules26061594"},{"issue":"3","key":"4712_CR30","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nprot.2006.179","volume":"1","author":"V Vichai","year":"2006","unstructured":"Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112\u20131116. https:\/\/doi.org\/10.1038\/nprot.2006.179","journal-title":"Nat Protoc"},{"issue":"1","key":"4712_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-016-0371-1","volume":"10","author":"D Massihnia","year":"2017","unstructured":"Massihnia D, Avan A, Funel N, Maftouh M, van Krieken A, Granchi C, Raktoe R, Boggi U, Aicher B, Minutolo F, Russo A, Leon LG, Peters GJ, Giovannetti E (2017) Phospho-akt overexpression is prognostic and can be used to tailor the synergistic interaction of akt inhibitors with gemcitabine in pancreatic cancer. J Hematol Oncol 10(1):9. https:\/\/doi.org\/10.1186\/s13045-016-0371-1","journal-title":"J Hematol Oncol"},{"issue":"12","key":"4712_CR32","first-page":"5668","volume":"12","author":"A Ali","year":"2022","unstructured":"Ali A, Jamieson NB, Khan IN, Chang D, Giovannetti E, Funel N, Frampton AE, Morton J, Sansom O, Evans TRJ, Duthie F, McKay CJ, Samra J, Gill AJ, Biankin A, Oien KA (2022) Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Am J Cancer Res 12(12):5668\u20135683","journal-title":"Am J Cancer Res"},{"key":"4712_CR33","doi-asserted-by":"publisher","first-page":"175883591984123","DOI":"10.1177\/1758835919841233","volume":"11","author":"TYS Le Large","year":"2019","unstructured":"Le Large TYS, El Hassouni B, Funel N, Kok B, Piersma SR, Pham TV, Olive KP, Kazemier G, van Laarhoven HWM, Jimenez CR, Bijlsma MF, Giovannetti E (2019) Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Ther Adv Med Oncol 11:1758835919841233. https:\/\/doi.org\/10.1177\/1758835919841233","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"4712_CR34","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/0008-5472.CAN-06-2484","volume":"67","author":"P Song","year":"2007","unstructured":"Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, Gravett C, Mark GP, Grando SA, Spindel ER (2007) M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 67(8):3936\u20133944. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2484","journal-title":"Cancer Res"},{"key":"4712_CR35","unstructured":"Crystal structure of human cartilage (2003) gp39 (HC-gp39) in complex with chitotetraose https:\/\/www.rcsb.org\/structure\/1NWU"},{"issue":"7","key":"4712_CR36","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1074\/jbc.M116.764985","volume":"292","author":"AA Kognole","year":"2017","unstructured":"Kognole AA, Payne CM (2017) Inhibition of mammalian glycoprotein YKL-40: IDENTIFICATION OF THE PHYSIOLOGICAL LIGAND. J Biol Chem 292(7):2624\u20132636. https:\/\/doi.org\/10.1074\/jbc.M116.764985","journal-title":"J Biol Chem"},{"issue":"5","key":"4712_CR37","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3748\/wjg.v20.i5.1127","volume":"20","author":"IA Lee","year":"2014","unstructured":"Lee IA, Kamba A, Low D, Mizoguchi E (2014) Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease. World J Gastroenterol 20(5):1127\u20131138. https:\/\/doi.org\/10.3748\/wjg.v20.i5.1127","journal-title":"World J Gastroenterol"},{"issue":"3","key":"4712_CR38","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1002\/jcb.27659","volume":"120","author":"M Zadi Heydarabad","year":"2019","unstructured":"Zadi Heydarabad M, Baharaghdam S, Azimi A, Mohammadi H, Eivazi Ziaei J, Yazdanpanah B, Zak MS, Farahani ME, Dohrabpour A, Partash N, Talebi M (2019) The role of tumor suppressor of resveratrol and prednisolone by downregulation of YKL-40 expression in CCRF-CEM cell line. J Cell Biochem 120(3):3773\u20133779. https:\/\/doi.org\/10.1002\/jcb.27659","journal-title":"J Cell Biochem"},{"key":"4712_CR39","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/1471-2407-10-593","volume":"10","author":"W Zhang","year":"2010","unstructured":"Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, Okada M, Miyake K, Kawai N, Fei Z, Tamiya T (2010) Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer 10:593. https:\/\/doi.org\/10.1186\/1471-2407-10-593","journal-title":"BMC Cancer"},{"issue":"9","key":"4712_CR40","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.chembiol.2005.07.009","volume":"12","author":"FV Rao","year":"2005","unstructured":"Rao FV, Andersen OA, Vora KA, Demartino JA, van Aalten DM (2005) Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes. Chem Biol 12(9):973\u2013980. https:\/\/doi.org\/10.1016\/j.chembiol.2005.07.009","journal-title":"Chem Biol"},{"key":"4712_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","volume":"189","author":"S Yamada","year":"2018","unstructured":"Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K (2018) Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther 189:130\u2013148. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.04.010","journal-title":"Pharmacol Ther"},{"issue":"18","key":"4712_CR42","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"issue":"1","key":"4712_CR43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13046-018-0876-2","volume":"37","author":"B Geng","year":"2018","unstructured":"Geng B, Pan J, Zhao T, Ji J, Zhang C, Che Y, Yang J, Shi H, Li J, Zhou H, Mu X, Xu C, Wang C, Xu Y, Liu Z, Wen H, You Q (2018) Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through beta-catenin\/Erk\/Akt signaling in gastric cancer. J Exp Clin Cancer Res 37(1):208. https:\/\/doi.org\/10.1186\/s13046-018-0876-2","journal-title":"J Exp Clin Cancer Res"},{"key":"4712_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","volume":"189","author":"S Yamada","year":"2018","unstructured":"Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K (2018) Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther 189:130\u2013148. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.04.010","journal-title":"Pharmacol Ther"},{"key":"4712_CR45","doi-asserted-by":"publisher","first-page":"116825","DOI":"10.1016\/j.biopha.2024.116825","volume":"176","author":"PC Su","year":"2024","unstructured":"Su PC, Chen CY, Yu MH, Kuo IY, Yang PS, Hsu CH, Hou YC, Hsieh HT, Chang CP, Shan YS, Wang YC (2024) Fully human chitinase-3 like-1 monoclonal antibody inhibits tumor growth, fibrosis, angiogenesis, and immune cell remodeling in lung, pancreatic, and colorectal cancers. Biomed Pharmacother 176:116825. https:\/\/doi.org\/10.1016\/j.biopha.2024.116825","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"4712_CR46","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1111\/j.1742-1241.2008.01893.x","volume":"62","author":"N Zinner","year":"2008","unstructured":"Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, Koochaki P (2008) Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract 62(11):1664\u20131674. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01893.x","journal-title":"Int J Clin Pract"},{"issue":"13","key":"4712_CR47","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.3390\/cancers13133220","volume":"13","author":"NA Hering","year":"2021","unstructured":"Hering NA, Liu V, Kim R, Weixler B, Droeser RA, Arndt M, Pozios I, Beyer K, Kreis ME, Seeliger H (2021) Blockage of Cholinergic Signaling via Muscarinic Acetylcholine Receptor 3 inhibits Tumor Growth in Human Colorectal Adenocarcinoma. Cancers 13(13):3220. https:\/\/doi.org\/10.3390\/cancers13133220","journal-title":"Cancers"},{"issue":"14","key":"4712_CR48","doi-asserted-by":"publisher","first-page":"18085","DOI":"10.18632\/oncotarget.7634","volume":"7","author":"T Yang","year":"2016","unstructured":"Yang T, He W, Cui F, Xia J, Zhou R, Wu Z, Zhao Y, Shi M (2016) MACC1 mediates acetylcholine-induced invasion and migration by human gastric cancer cells. Oncotarget 7(14):18085\u201318094. https:\/\/doi.org\/10.18632\/oncotarget.7634","journal-title":"Oncotarget"},{"key":"4712_CR49","doi-asserted-by":"publisher","first-page":"40802","DOI":"10.1038\/srep40802","volume":"7","author":"H Yu","year":"2017","unstructured":"Yu H, Xia H, Tang Q, Xu H, Wei G, Chen Y, Dai X, Gong Q, Bi F (2017) Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes gastric cancer cell proliferation. Sci Rep 7:40802. https:\/\/doi.org\/10.1038\/srep40802","journal-title":"Sci Rep"},{"issue":"12","key":"4712_CR50","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1158\/0008-5472.CAN-08-0183","volume":"68","author":"P Song","year":"2008","unstructured":"Song P, Sekhon HS, Fu XW, Maier M, Jia Y, Duan J, Proskosil BJ, Gravett C, Lindstrom J, Mark GP, Saha S, Spindel ER (2008) Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res 68(12):4693\u20134700. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0183","journal-title":"Cancer Res"},{"issue":"5","key":"4712_CR51","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00428-003-0784-4","volume":"442","author":"B Sipos","year":"2003","unstructured":"Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G (2003) A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442(5):444\u2013452. https:\/\/doi.org\/10.1007\/s00428-003-0784-4","journal-title":"Virchows Arch"},{"key":"4712_CR52","doi-asserted-by":"publisher","first-page":"118134","DOI":"10.1016\/j.lfs.2020.118134","volume":"258","author":"K Bhatia","year":"2020","unstructured":"Bhatia K, Bhumika, Das A (2020) Combinatorial drug therapy in cancer - new insights. Life Sci 258:118134. https:\/\/doi.org\/10.1016\/j.lfs.2020.118134","journal-title":"Life Sci"},{"issue":"2","key":"4712_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1574889809666141120131238","volume":"9","author":"C Matera","year":"2014","unstructured":"Matera C, Tata AM (2014) Pharmacological approaches to targeting muscarinic acetylcholine receptors. Recent Pat CNS Drug Discov 9(2):85\u2013100. https:\/\/doi.org\/10.2174\/1574889809666141120131238","journal-title":"Recent Pat CNS Drug Discov"},{"key":"4712_CR54","doi-asserted-by":"publisher","unstructured":"Schledwitz A, Sundel MH, Alizadeh M, Hu S, Xie G, Raufman JP (2021) Differential actions of muscarinic receptor subtypes in gastric, pancreatic, and Colon cancer. Int J Mol Sci 22(23). https:\/\/doi.org\/10.3390\/ijms222313153","DOI":"10.3390\/ijms222313153"},{"issue":"7","key":"4712_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrd4295","volume":"13","author":"AC Kruse","year":"2014","unstructured":"Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J (2014) Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 13(7):549\u2013560. https:\/\/doi.org\/10.1038\/nrd4295","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"4712_CR56","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1517\/13543784.13.11.1493","volume":"13","author":"CR Chapple","year":"2004","unstructured":"Chapple CR (2004) Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 13(11):1493\u20131500. https:\/\/doi.org\/10.1517\/13543784.13.11.1493","journal-title":"Expert Opin Investig Drugs"},{"key":"4712_CR57","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.2147\/OTT.S111382","volume":"9","author":"L Zhang","year":"2016","unstructured":"Zhang L, Xiu D, Zhan J, He X, Guo L, Wang J, Tao M, Fu W, Zhang H (2016) High expression of muscarinic acetylcholine receptor 3 predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Onco Targets Ther 9:6719\u20136726. https:\/\/doi.org\/10.2147\/OTT.S111382","journal-title":"Onco Targets Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04712-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04712-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04712-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:02:29Z","timestamp":1727535749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04712-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["4712"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04712-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the protocols were approved by the local Hospital Ethic Committees of the Mashhad University of Medical Sciences (protocol number IR.MUMS.MEDICAL.REC.1400.709), and by the Ethics Committee of Area Vasta Nord Ovest (CEAVNO) (protocol code 724).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}